RxDoctor Payments Data

Samir Kanani, MD

Radiation Oncology · Fairfax, VANPI 1558336719

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $72,350 of the $89,891 with a category attached, or 80.5%. Novocure Inc. accounts for 96.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $18,789 and has fallen 95.3% since, to $881 in 2025. Among radiation oncology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,891in general payments, 2019–2025

Across 154 payments — averaging $583.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$87K
  • Boston Scientific$609
  • Palette Life Sciences, Inc.$528
  • Teleflex LLC$289
  • Integra Lifesciences Corporation$166
  • Medtronic$140
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$3,9004%
  • Speaking & faculty fees$72,35080%
  • Travel & lodging$7,7229%
  • Food & beverage$5,8146%
  • Education$1050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,891 in reported general payments places this provider in the 95th percentile of 121 radiation oncology providers in Virginia.

See all radiation oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$413,700
Medicare patients
194
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →